FY2017 Earnings Estimate for Lipocine Inc. Issued By Zacks Investment Research (NASDAQ:LPCN)
Lipocine Inc. (NASDAQ:LPCN) – Analysts at Zacks Investment Research boosted their FY2017 earnings estimates for Lipocine in a research report issued to clients and investors on Tuesday. Zacks Investment Research analyst J. Vandermosten now expects that the specialty pharmaceutical company will earn ($1.16) per share for the year, up from their previous forecast of ($1.17).
Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.01.
TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/10/fy2017-earnings-estimate-for-lipocine-inc-issued-by-zacks-investment-research-nasdaqlpcn.html.
Several other analysts also recently issued reports on the stock. Roth Capital set a $38.00 target price on shares of Lipocine and gave the company a “buy” rating in a research note on Tuesday, June 20th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Lipocine in a research note on Wednesday, April 26th. Canaccord Genuity set a $10.00 target price on shares of Lipocine and gave the company a “buy” rating in a research note on Monday, April 24th. Finally, ValuEngine downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday.
Lipocine (NASDAQ LPCN) opened at 4.32 on Thursday. Lipocine has a 52-week low of $3.03 and a 52-week high of $5.90. The firm’s 50-day moving average price is $4.45 and its 200 day moving average price is $3.99. The stock’s market cap is $83.21 million.
A number of hedge funds have recently made changes to their positions in LPCN. Ameriprise Financial Inc. increased its stake in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock valued at $513,000 after buying an additional 65,600 shares during the period. LMR Partners LLP purchased a new stake in shares of Lipocine during the second quarter valued at about $173,000. Parametric Portfolio Associates LLC increased its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares during the period. Federated Investors Inc. PA increased its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 7,429 shares during the period. Finally, KCG Holdings Inc. increased its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 7,219 shares during the period. 38.88% of the stock is currently owned by institutional investors.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.